- Home
- LXRX
as 12-17-2024 4:00pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 352.5M | IPO Year: | 2000 |
| Target Price: | $6.00 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $3.73 | Next Earning Date: | 11-12-2024 |
| Revenue: | $5,229,000 | Revenue Growth: | 886.60% |
| Revenue Growth (this year): | 886.38% | Revenue Growth (next year): | 181.58% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
21 days ago
Lexicon completes subject enrolment for DPNP trial of LX9211
GlobeNewswire
22 days ago
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
GlobeNewswire
23 days ago
Lexicon Pharmaceuticals to Participate in December Investor Conferences
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating
MT Newswires
a month ago
Lexicon Pharmaceuticals to Cut 60% of Workforce
GlobeNewswire
a month ago
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
BioPharma Dive
a month ago
Lexicon to disband sales team, lay off 60% of staff
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.